AAAAAA
Results:
1-10
|
Results: 10
Authors:
Wasserman, TH
Brizel, DM
Citation: Th. Wasserman et Dm. Brizel, The role of amifostine as a radioprotector, ONCOLOGY-NY, 15(10), 2001, pp. 1349-1354
Authors:
Press, OW
LeBlanc, M
Lichter, AS
Grogan, TM
Unger, JM
Wasserman, TH
Gaynor, ER
Peterson, BA
Miller, TP
Fisher, RI
Citation: Ow. Press et al., Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease, J CL ONCOL, 19(22), 2001, pp. 4238-4244
Authors:
Owen, JB
Grigsby, PW
Caldwell, TM
Konski, AA
Johnson, DJ
Demas, WF
Movsas, B
Jones, CU
Wasserman, TH
Citation: Jb. Owen et al., Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the Radiation Therapy Oncology Group (RTOG) studies 90-03 and 91-04, INT J RAD O, 49(3), 2001, pp. 633-639
Authors:
Wasserman, TH
Brizel, DM
Citation: Th. Wasserman et Dm. Brizel, Has the outlook improved for amifostine as a clinical radioprotector?, RADIOTH ONC, 60(3), 2001, pp. 334-335
Authors:
Cutuli, B
Borel, C
Dhermain, F
Magrini, SM
Wasserman, TH
Bogart, JA
Provencio, M
de Lafontan, B
de la Rochefordiere, A
Cellai, E
Graic, Y
Kerbrat, P
Alzieu, C
Teissier, E
Dilhuydy, JM
Mignotte, H
Velten, M
Citation: B. Cutuli et al., Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases, RADIOTH ONC, 59(3), 2001, pp. 247-255
Authors:
Brizel, DM
Wasserman, TH
Henke, M
Strnad, V
Rudat, V
Monnier, A
Eschwege, F
Zhang, J
Russell, L
Oster, W
Sauer, R
Citation: Dm. Brizel et al., Phase III randomized trial of amifostine as a radioprotector in head and neck cancer, J CL ONCOL, 18(19), 2000, pp. 3339-3345
Authors:
Perez, CA
Michalski, JM
Purdy, JA
Wasserman, TH
Williams, K
Lockett, MA
Citation: Ca. Perez et al., Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: Preliminary results of a nonrandomized comparison, INT J RAD O, 47(3), 2000, pp. 629-637
Authors:
Hensley, ML
Schuchter, LM
Lindley, C
Meropol, NJ
Cohen, GI
Broder, G
Gradishar, WJ
Green, DM
Langdon, RJ
Mitchell, B
Negrin, R
Szatrowski, TP
Thigpen, JT
Von Hoff, D
Wasserman, TH
Winer, EP
Pfister, DG
Citation: Ml. Hensley et al., American Society of Clinical Oncology clinical practice guidelines for theuse of chemotherapy and radiotherapy protectants, J CL ONCOL, 17(10), 1999, pp. 3333-3355
Authors:
Grigsby, PW
Winter, K
Wasserman, TH
Marcial, V
Rotman, M
Cooper, J
Keys, H
Asbell, SO
Phillips, TL
Citation: Pw. Grigsby et al., Irradiation with or without misonidazole for patients with stages IIIB andIVA carcinoma of the cervix: Final results of RTOG 80-05, INT J RAD O, 44(3), 1999, pp. 513-517
Authors:
Wasserman, TH
Petroni, GR
Millard, FE
Chung, CT
Barcos, M
Johnson, JL
Canellos, GP
Peterson, BA
Citation: Th. Wasserman et al., Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features - A phase II Cancer and Leukemia Group B study (9051), CANCER, 86(8), 1999, pp. 1590-1595
Risultati:
1-10
|